Introduction
Breast cancer is the most common cause of cancerrelated death among women in Thailand. Since the introduction of the molecular subtypes of breast carcinoma in 2000, breast cancer has been classified based on gene expression profiling into 5 subtypes including: luminal A [estrogen receptor(ER)+, HER2-], luminal B [ER+, HER2+], HER2, triple negative (TN, ER-and HER2-) basal-like (TNB), and TN without basal-like markers (TNN, null/normal breast-like) (Perou et al., 2000; Sorlie et al., 2001; Sotiriou et al., 2003) . The TN group does not benefit from hormonal therapies or treatment targeted against HER2 receptors. The majority of TNB subtype consistently harbored genes usually found in normal basal/ myoepithelial cells of breast including high-molecularweight 'basal' cytokeratins (CKs, 5, 14 and 17) , vimentin, p-cadherin, aB crystalline, fascin and caveolins 1 and 2 (Nielsen et al., 2004; Irvin and Carey, 2008 studies of basal-like subtype breast cancer revealed p53 expression immunohistochemically or TP53 gene mutation, displayed high levels of proliferation related genes and EGFR expression (Nielsen et al., 2004; Kim et al., 2006) . The TNB subtype has an intimate association with BRCA1 function (Foulkes et al., 2003) , often affects younger patients, has aggressive clinical behavior and poor prognosis. Now there are some remarkable advances in the treatment of breast cancer with combination of chemotherapies, hormonal, and modern targeted therapies which signify the importance of the diagnosis of certain subtypes (Nielsen et al., 2004; Livasy et al., 2006; ReisFilho and Tutt, 2008) . The relation of basal-like subtype with epidermal growth factor receptor (EGFR) (Nielsen et al., 2004; Kim et al., 2006) and/or angiogenesis (vascular endothelial growth factor, VEGF) if present could lead to the role of targeted therapy. Since the use of immunohistochemical markers to classify basal-like subtype (Nielsen et al., 2004) there have been many studies from many countries using immunomarkers to classify breast cancers according to molecular subtypes (Kim et al., 2006; Reis-Filho and Tutt, 2008; Thike et al., 2010) . In a recent consensus at St. Gallen, 2011 related to treatment strategies, immunohistochemical staining of Ki-67 has been additionally used to classify ER+ HER2-subgroup into luminal A (ER+, HER2-, Ki-67≤14%), and luminal B (HER2-subgroup) (ER+, HER2-, Ki-67>14%) (Goldhirsch et al., 2011) . The new classification on breast cancers by using immuohistochemical markers of basallike markers including EGFR has not been reported in Thai patients before. We use immunomarkers on tissue microarrays (TMA) to classify subtypes, study their clinicopathologic features and correlate each subtype with the prognostic markers, Ki-67 index and p53 expression, microvessel density (MVD) and VEGF expression.
Chaiwun et al reported a prevalence (35.9%) and high grade character of the TN in their study of high-nucleargrade breast cancer in Thailand (Chaiwun et al., 2010) but the new classification by using immuohistochemical markers on tissue microarrays (TMA) of the general breast cancers has not been reported in Thai patients before. To validate the prevalence of the subtypes, their clinicopathologic features and clinical status a panel of basal-like immunomarkers was used. We also correlate each subtype with the prognostic markers, Ki-67 index and p53 expression, microvessel density (MVD) and VEGF expression.
Materials and Methods
This study was approved by the Institutional Review Board of Faculty of Medicine Siriraj Hospital No. R015332015 and included 100 mastectomy cases with adequate material for study. All cases were obtained during 2002-2004 from the Department of Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University previously enrolled in the study of 'The role of the vascular endothelial growth factor polymorphisms in Thai breast cancer patients (Sa-Nguanraksa et al., 2013) .
The histology was reviewed including type, grade (modified Bloom-Richardson classification), lymphovascular invasion (LVI) and nodal status. Three cores of 2 mm diameter from each case plus 6 controls were constructed yielded 6 TMA blocks. Each set was stained for ER, PR, HER2, markers of basal-like subtype (three basal cytokeratins, CK 5, CK14, and CK17, EGFR, CD117 and p63) ( Table 1) . Prognostic factors as p53, vimentin and Ki-67 immunohistochemistry (IHC) were also performed. The IHC performed were evaluated by TC, TP, and SW without knowledge of clinical outcomes. Cases were classified into: 1) luminal A (ER+ and/or PR+, HER2-, Ki-67≤14%), 2) luminal B (ER+ and/or PR+, HER2+ or ER+ and/or PR+, HER2-, Ki-67>14%), 3) HER2 (ER-, PR-, HER2+), 4) TN basal-like (TNB) (ER-, PR-, HER2-, with at least any CK5+, CK14+, CK17+ or EGFR+) and 5) TN without basal-like markers (TNN) (ER-, PR-, HER2-, CK5-, CK14-, CK17-, EGFR-). Expression of VEGF was assessed semiquantitatively using H scores (Table 1 ). The median of the score was used as a cut-off level to categorize tumors into low-and high-expressing tumors (Yang et al., 2002) . The median of MVD was used as the cut-off level to categorize tumors into low-and high-MVD tumors. Clinical information including mode of treatment and survival status was assessed.
For statistical analysis, the Chi-square test or Fisher's Exact test were used. The age, size of tumor, Ki-67 index, the percentage of VEGF expression (H score) and MVD count were reported using descriptive statistics and Mann Whitney U test to compare the mean of the variables between subtypes. The follow-up period was defined as the time from diagnosis to the last visit/observation or death. Disease-free survival (DFS) was defined as the time between the date of the diagnosis to the date of relapse or August 2011. Overall survival (OS) was defined as the time between the date of the diagnosis to the date of death or August 2011. The log-rank test was used to estimate and compare survival. A p value of <0.05 was considered statistically significant.
Results

Overall characteristics
All patients were women, age ranged from 25-85 years (mean 51, median 50). There were 89 invasive ductal carcinoma (IDC), not otherwise specified (NOS), 4 invasive lobular (ILC), 3 metaplastic carcinoma, 2 mixed-type carcinomas, 1 invasive micropapillary, and 1 carcinosarcoma. The tumor size ranged from 0.24-11.5 cm (mean 3.2, median 3.0). Surgical treatment from 99 patients included modified radical mastectomy (32%), total mastectomy (63%) and breast conserving surgery (5%). The latter two were performed with axillary node dissection (sentinel with/without non-sentinel lymph node dissection). Of 99 cases, 15, 49, 29, and 6% were in stages 1, 2, 3, and 4, respectively; 56% had positive axillary nodes of which 55% had perinodal invasion; 48% had LVI. The follow up time ranged from 2-101 months (mean, 81). 71% were disease-free, 17% had relapse or metastasis and 12% died of disease.
Subtypes of breast cancers classified by hormonal receptors, HER2 and basal cytokeratins and EGFR immunohistochemical studies
There were 39% of luminal A, 18% of luminal B [10% of luminal B (HER2+), 8% of luminal B (HER2-)], 18% of HER2, and 25% of TN (15%TNB, and 10% TNN) subtypes.
Immunohistochemical studies of each subtype (Table 2) ER, PR and HER2 were expressed in 57, 38 and 28%, respectively. In the hormonal receptor positive suptypes ER was positive in all while PR was positive in 58.9 and 83.3% of luminal A and luminal B, respectively.
Basal-like biomarkers (Table 2)
Basal CKs: (CK 5, CK14, and CK17) When all three were used 80% of TNB could be diagnosed. Among these, CK5 had a greater sensitivity (73%) in detecting basal-like subtype when compared with cytokeratins DOI:http://dx.doi.org/10.7314/APJCP.2014.15.3.1187 Molecular Subtype of Breast Cancer, MVD and VEGF Expression 14 and 17 but a lower specificity when compared with cytokeratin 14 alone or combined CKs since basal CKs could be expressed in subtypes other than basal-like as was present in 1 case of luminal A with minimal quantity of CK5 (>1<10%) and in 1 luminal B with all three CKs. Basal CKs were also found in 4 (22.2%) of HER2, 3 of which had CK5 alone, and the other one with only CK17. No basal CK was found in luminal B.
EGFR: this protein was detected in 7 cases (46.7%) of TNB and 5 cases (27.8%) of HER2; 20% of TNB had positive EGFR alone and 26.7% had a combination of EGFR and one or more basal CKs. Four of 5 (EGFER+) HER2 subtype also expressed CK5.
CD117: it was detected in 4 cases (26.7%) of TNB, 1 luminal A and 1 HER2. p63: this protein had a low sensitivity (33.3% positive) comparing with basal CKs in detecting TNB; 3 out of 5 positive cases were 2 metaplastic carcinomas and 1 carcinosarcoma. It was also found in other subtypes (2-20%)
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Vimentin: it was significantly expressed in TNB (46.7%, compared with 11.1% and 10% in HER2 and TNN, p<0.001).
p53: Tthis protein was expressed in more than 50% of each subtype except for luminal A (21.3%). It was significantly markedly expressed in 70% of TNN (overall p=0.001) Ki-67 index: A total of 91 cases could be evaluated due to inadequate tissue in some cores. This index was significantly increased in TNB with an average value of 18.07% (SD=13.1, range 4-44.3%) when compared with luminal A (p=0.005) and HER2 subtype (p=0.042), but not significantly increased when compared with luminal B (p=0.337) and TNN (p=0.283). When comparing the Table 2 . Also there was no significant increase in VEGF positive cells in basal-like subtype as compared with others (p=0.264) ( Table 2) There was no correlation of CK5 expression and high VEGF expression (p=0.796)
Clinico-pathological parameters (Table 3)
There was no significant difference in the age of the patients among subtypes (p=0.265). Four out of 9 patients (44%) in the TNB had a family history of breast/ovarian cancer while others had this history in 13-17%.
Comparison of clinic-pathological data among TNB, TNN and non-TN subtypes: (Table 4)
TN carcinomas had significant high histologic grade (p=0.038), and significant high mitotic count (p=0.03). There were no significant differences in tumor size, tubule formation, nuclear pleomorphism, LVI, pathological :http://dx.doi.org/10.7314/APJCP.2014.15.3.1187 Molecular Subtype of Breast Cancer, MVD and VEGF Expression (Kim et al., 2006) . TN subtype in the previous reports varied from 10-17% (Reis-Filho and Tutt, 2008) . It was 17.6% without racial difference from the study from Malaysia (Tan et al., 2009 ) and 11% from Singapore (Thike et al., 2010) while in our study it was 25% (TNB,15%). Our prevalence of TN was quite different from that of Singapore despite using the same positive criteria of HER2 and the lower ER cut off value of ours. Among basal-like markers, similar to previous studies CK5 was the more sensitive but less specific in determining basal-like subtype compared with CK14 (Nielsen et al., 2004; Kim et al., 2006) and could demonstrate 73%TNB in our study. CK17 was the least sensitive. On the contrary CK17 was the most sensitive but CK5/6 was the least one in the study of Thike et al., 2010 . The frequencies of CD117 and p63 in TNB and other subtypes were comparable to previous reports (Nielsen et al., 2004; Kim et al., 2006) as well as EGFR immunoreactivity which ranged from 44-72% (Nielsen et al., 2004; Kim et al., 2006) . Different EGFR clone may have varying sensitivity thus affecting the differential diagnosis between TNB and TNN. This marker and CK5 were 80% present together in nearly one third of HER2 subtype in our study. Regarding the prognostic /predictive markers, Ki-67, p53 and vimentin were highly expressed in the basal-like comparable to other reports (Nielsen et al., 2004; Kim et al., 2006; Livasy et al., 2006; Han et al., 2010) .
Regarding the clinico-pathologic features the results were similar to others, the TN compared with nonTN displayed high grade tumor (Sotiriou et al., 2003; Nielsen et al., 2004; Carey et al., 2006; Kim et al., 2006; Livasy et al., 2006; Irvin et al,, 2008; Reis-Filho and Tutt, 2008; Tan et al., 2009; Chaiwun et al., 2010; Thike et al., 2010) ; no significant correlation was found in patients' age, tumor size, LVI, axillary node status, and staging (Kim et al., 2006) . The association between MVD and VEGF expression in our study existed but correlation of these markers among subtypes nor correlation between CK5 and high VEGF expression could not be found probably due to the small sample size. From a few reports on the latter two, the basal-like had higher VEGF expression, correlation with CK5 expression but no significant higher MVD (Ribeiro-Silva, 2006; Lopes et al., 2009) . Recently, in a study of 1788 invasive ductal carcinomas from the Nurses' Health Study, VEGF expression was found to correlate with intrinsic subtypes with higher frequency in luminal B, HER2, and basal-like versus luminal A subtypes; it was not significantly related to poor survival staging, VEGF (count and H score) and MVD. (Figures 1 and 2) TN had significant decreased OS when compared with all nonTN (p=0.047) but no significant difference among patients of all subtypes (p=0.250); TNB versus others (p=0.08); TNB versus TNN (p=0.794); luminal B and HER2 versus others (p=0.881); HER2 versus luminal A and luminal B (p=0.256).
Correlation of phenotypes and survivals
There was no significant difference in DFS among patients of all subtypes (p=0.874); TN versus all nonTN (p=0.784); luminal B and HER2 versus others (p=0.366)
Discussion
The prevalence of breast cancer subtypes classified by biomarkers could vary not only from the ethnicity (Carey et al., 2006; Thike et al., 2010) but may depend on the method used, biomarker profile, clone of the antibody, laboratory technique and criteria of evaluation. In comparison with the data obtained from the study of 324 Thai breast carcinomas (Chuthapisith et al., 2012) there were 59.3% luminal A, 12.3% luminal B, 13.3% HER2 and 15.1% TN while from the current study of 100 TMA cases when transformed to the comparable data there were but was significantly associated with increased risks for breast cancer-specific mortality and distant recurrence among women with luminal A tumors (Liu et al., 2011) .
Many reports signified poor outcomes in HER2 and TN subgroup (Sorlie et al., 2001; Kim et al., 2006; Dent et al., 2007; Spitale et al., 2009) . Our study failed to demonstrate significant difference in survival among 5 subtypes except for OS difference between TN and non-TN groups. We could not find survival difference between the non-basal-like and basal-like tumors similar to the study using immunohistochemical and geneexpression-based classification (Jumppanen et al., 2007) . The explanation for this result in our study could be due to the small sample size. More cases should be studied to find the clinical significance of the TNB and TNN and any biomarkers that could predict the clinical outcome other than the ones that we used to classify these two subtypes. Recently calretinin expression had been found to correlate with poor clinical outcome in TNB subtype (Taliano et al., 2013) . We did not study this marker in the current study.
In conclusion: biomarkers identified 25%of Thai breast cancers as TN, 52%of which were basal-like. TNB phenotype had high tumor grade, mitotic count and Ki67-index. Besides TNB, EGFR expression could be seen in HER2. No different MVD or VEGF expression or poor clinical outcomes were observed among subtypes. However, TN had decreased overall survival when compared with nonTN. Further study with more samples should be done.
